Comparison of the Abbott Real-Time CT New Formulation Assay with Two Other Commercial Assays for Detection of Wild-type and New Variant Strains of Chlamydia trachomatis

Jens Kjølseth Møller, Lisbeth Nørum Pedersen, Kenneth Persson

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2009-Dec-9
OriginalsprogEngelsk
TidsskriftJournal of Clinical Microbiology
Vol/bind48
Udgave nummer2
Sider (fra-til)440-443
Antal sider3
ISSN0095-1137
DOI
StatusUdgivet - 9. dec. 2009

Fingeraftryk

Chlamydia trachomatis
Urine
Polymerase Chain Reaction
Real-Time Polymerase Chain Reaction
Denmark

Citer dette

@article{df3111e0029211dfaefb000ea68e967b,
title = "Comparison of the Abbott Real-Time CT New Formulation Assay with Two Other Commercial Assays for Detection of Wild-type and New Variant Strains of Chlamydia trachomatis",
abstract = "In an analytical methods comparison study on clinical samples, the Abbott RealTime CT new formulation assay (m2000 real-time PCR) consisting of a duplex PCR targeting different parts of the cryptic plasmid in Chlamydia trachomatis was compared with version 2 of the Roche COBAS(R) TaqMan(R) CT assay comprising a duplex PCR for a target in the cryptic plasmid and the omp1 gene, and compared with the Gen-Probe APTIMA COMBO 2(R) assay (AC2) targeting the C. trachomatis 23S rRNA molecule. First-catch urine samples from Sweden were tested in Malmoe for C. trachomatis with the m2000 real-time PCR assay, and with an in-house PCR for the new variant C. trachomatis strain with a deletion in the cryptic plasmid. Aliquots of the urine samples were sent to Aarhus, Denmark and further examined with the TaqMan CT and the AC2 assay. A positive prevalence of 9.1{\%} (148/1,632 urine samples examined) was detected according to the combined reference standard. The sensitivity and specificity of the three assays were as follows: for Abbott m2000, 95.3{\%} (141/148) and 99.9{\%} (1,483/1,485), respectively; for Roche TaqMan, 82.4{\%} (122/148) and 100.0{\%} (1,485/1,485); for Gen-Probe AC2, 99.3{\%} (147/148) and 99.9{\%} (1,484/1,485). The plasmid mutant strain was detected in 24{\%} (36/148) of the C. trachomatis positive samples. There is a difference in sensitivity between the new formulation of the Abbott and the Roche assays, but both assays detected the wild-type and the new variant C. trachomatis strains equally well.",
author = "M{\o}ller, {Jens Kj{\o}lseth} and Pedersen, {Lisbeth N{\o}rum} and Kenneth Persson",
year = "2009",
month = "12",
day = "9",
doi = "10.1128/JCM.01446-09",
language = "English",
volume = "48",
pages = "440--443",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "2",

}

Comparison of the Abbott Real-Time CT New Formulation Assay with Two Other Commercial Assays for Detection of Wild-type and New Variant Strains of Chlamydia trachomatis. / Møller, Jens Kjølseth; Pedersen, Lisbeth Nørum; Persson, Kenneth.

I: Journal of Clinical Microbiology, Bind 48, Nr. 2, 09.12.2009, s. 440-443.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Comparison of the Abbott Real-Time CT New Formulation Assay with Two Other Commercial Assays for Detection of Wild-type and New Variant Strains of Chlamydia trachomatis

AU - Møller, Jens Kjølseth

AU - Pedersen, Lisbeth Nørum

AU - Persson, Kenneth

PY - 2009/12/9

Y1 - 2009/12/9

N2 - In an analytical methods comparison study on clinical samples, the Abbott RealTime CT new formulation assay (m2000 real-time PCR) consisting of a duplex PCR targeting different parts of the cryptic plasmid in Chlamydia trachomatis was compared with version 2 of the Roche COBAS(R) TaqMan(R) CT assay comprising a duplex PCR for a target in the cryptic plasmid and the omp1 gene, and compared with the Gen-Probe APTIMA COMBO 2(R) assay (AC2) targeting the C. trachomatis 23S rRNA molecule. First-catch urine samples from Sweden were tested in Malmoe for C. trachomatis with the m2000 real-time PCR assay, and with an in-house PCR for the new variant C. trachomatis strain with a deletion in the cryptic plasmid. Aliquots of the urine samples were sent to Aarhus, Denmark and further examined with the TaqMan CT and the AC2 assay. A positive prevalence of 9.1% (148/1,632 urine samples examined) was detected according to the combined reference standard. The sensitivity and specificity of the three assays were as follows: for Abbott m2000, 95.3% (141/148) and 99.9% (1,483/1,485), respectively; for Roche TaqMan, 82.4% (122/148) and 100.0% (1,485/1,485); for Gen-Probe AC2, 99.3% (147/148) and 99.9% (1,484/1,485). The plasmid mutant strain was detected in 24% (36/148) of the C. trachomatis positive samples. There is a difference in sensitivity between the new formulation of the Abbott and the Roche assays, but both assays detected the wild-type and the new variant C. trachomatis strains equally well.

AB - In an analytical methods comparison study on clinical samples, the Abbott RealTime CT new formulation assay (m2000 real-time PCR) consisting of a duplex PCR targeting different parts of the cryptic plasmid in Chlamydia trachomatis was compared with version 2 of the Roche COBAS(R) TaqMan(R) CT assay comprising a duplex PCR for a target in the cryptic plasmid and the omp1 gene, and compared with the Gen-Probe APTIMA COMBO 2(R) assay (AC2) targeting the C. trachomatis 23S rRNA molecule. First-catch urine samples from Sweden were tested in Malmoe for C. trachomatis with the m2000 real-time PCR assay, and with an in-house PCR for the new variant C. trachomatis strain with a deletion in the cryptic plasmid. Aliquots of the urine samples were sent to Aarhus, Denmark and further examined with the TaqMan CT and the AC2 assay. A positive prevalence of 9.1% (148/1,632 urine samples examined) was detected according to the combined reference standard. The sensitivity and specificity of the three assays were as follows: for Abbott m2000, 95.3% (141/148) and 99.9% (1,483/1,485), respectively; for Roche TaqMan, 82.4% (122/148) and 100.0% (1,485/1,485); for Gen-Probe AC2, 99.3% (147/148) and 99.9% (1,484/1,485). The plasmid mutant strain was detected in 24% (36/148) of the C. trachomatis positive samples. There is a difference in sensitivity between the new formulation of the Abbott and the Roche assays, but both assays detected the wild-type and the new variant C. trachomatis strains equally well.

U2 - 10.1128/JCM.01446-09

DO - 10.1128/JCM.01446-09

M3 - Journal article

VL - 48

SP - 440

EP - 443

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 2

ER -